The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Anton, R. F.
* Articles by Dias, J. K.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Anton, R. F.
* Articles by Dias, J. K.
Related Collections
* Alcohol
* Behavior Therapy
* Cognitive Therapy
* Other Somatic Therapy
Am J Psychiatry 156:1758-1764, November 1999
© 1999 American Psychiatric Association

Regular Article

Naltrexone and Cognitive Behavioral Therapy for the Treatment of Outpatient Alcoholics: Results of a Placebo-Controlled Trial

Raymond F. Anton, M.D., Darlene H. Moak, M.D., L. Randolph Waid, Ph.D., Patricia K. Latham, R.N., Ph.D., Robert J. Malcolm, M.D., and James K. Dias, Ph.D.

OBJECTIVE: The opiate antagonist drug naltrexone has been shown in a few studies with limited sample sizes to be effective when combined with psychosocial therapies for the treatment of alcohol dependence. The goal of this study was to obtain additional information regarding its efficacy in pertinent alcoholic populations and with a well-defined therapy. METHOD: In this study, 131 recently abstinent alcohol-dependent outpatients were treated with 12 weekly sessions of manual-guided cognitive behavioral therapy and either 50 mg/day of naltrexone (N=68) or placebo (N=63) (with riboflavin added as a marker of compliance) in a double-blind, randomized clinical trial. Alcohol consumption, craving, adverse events, and urinary riboflavin levels were assessed weekly. Levels of blood markers of alcohol abuse were also ascertained during the trial. RESULTS: The study completion, therapy participation, and medication compliance rates in the trial were high, with no differences between treatment groups. Naltrexone-treated subjects drank less, took longer to relapse, and had more time between relapses. They also exhibited more resistance to and control over alcohol-related thoughts and urges, as measured by a subscale of the Obsessive Compulsive Drinking Scale. Over the study period, 62% of the naltrexone group did not relapse into heavy drinking, in comparison with 40% of the placebo group. CONCLUSIONS: Motivated individuals with moderate alcohol dependence can be treated with greater effectiveness when naltrexone is used in conjunction with weekly outpatient cognitive behavioral therapy. Naltrexone increases control over alcohol urges and improves cognitive resistance to thoughts about drinking. Thus, the therapeutic effects of cognitive behavioral therapy and naltrexone may be synergistic.




This article has been cited by other articles:


Home page
 NEJMHome page
R. F. Anton
Naltrexone for the Management of Alcohol Dependence
N. Engl. J. Med., August 14, 2008; 359(7): 715 - 721.
[Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
H. Myrick, R. F. Anton, X. Li, S. Henderson, P. K. Randall, and K. Voronin
Effect of Naltrexone and Ondansetron on Alcohol Cue-Induced Activation of the Ventral Striatum in Alcohol-Dependent People
Arch Gen Psychiatry, April 1, 2008; 65(4): 466 - 475.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
R. F. Anton, G. Oroszi, S. O'Malley, D. Couper, R. Swift, H. Pettinati, and D. Goldman
An Evaluation of {micro}-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol Dependence: Results From the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) Study
Arch Gen Psychiatry, February 1, 2008; 65(2): 135 - 144.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
S. Rosner, S. Leucht, P. Lehert, and M. Soyka
Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes
J Psychopharmacol, January 1, 2008; 22(1): 11 - 23.
[Abstract] [PDF]

Home page
 Alcohol AlcoholHome page
E. Laaksonen, A. Koski-Jannes, M. Salaspuro, H. Ahtinen, and H. Alho
A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence
Alcohol Alcohol., January 1, 2008; 43(1): 53 - 61.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
L. A. Ray and K. E. Hutchison
Effects of Naltrexone on Alcohol Sensitivity and Genetic Moderators of Medication Response: A Double-blind Placebo-Controlled Study
Arch Gen Psychiatry, September 1, 2007; 64(9): 1069 - 1077.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
A. M. Peterson
Improving adherence in patients with alcohol dependence: A new role for pharmacists
Am. J. Health Syst. Pharm., March 1, 2007; 64(5_Supplement_3): S23 - S29.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
I. L. Petrakis, C. Nich, and E. Ralevski
Psychotic Spectrum Disorders and Alcohol Abuse: A Review of Pharmacotherapeutic Strategies and a Report on the Effectiveness of Naltrexone and Disulfiram
Schizophr Bull, October 1, 2006; 32(4): 644 - 654.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
B. J. Mason
Acamprosate for Alcohol Dependence: An Update for the Clinician
Focus, September 1, 2006; 4(4): 505.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
J. E. Grant, M. N. Potenza, E. Hollander, R. Cunningham-Williams, T. Nurminen, G. Smits, and A. Kallio
Multicenter Investigation of the Opioid Antagonist Nalmefene in the Treatment of Pathological Gambling
Am J Psychiatry, February 1, 2006; 163(2): 303 - 312.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. C. Garbutt, H. R. Kranzler, S. S. O'Malley, D. R. Gastfriend, B. L. Silverman, J. W. Loewy, E. W. Ehrich, and H. M. Pettinati
Naltrexone Treatment for Alcohol Dependency--Reply
JAMA, August 24, 2005; 294(8): 900 - 900.
[Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
C. P. O'Brien
Anticraving Medications for Relapse Prevention: A Possible New Class of Psychoactive Medications
Am J Psychiatry, August 1, 2005; 162(8): 1423 - 1431.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
G. RUBIO, G. PONCE, R. RODRIGUEZ-JIMENEZ, M. A. JIMENEZ-ARRIERO, J. HOENICKA, and T. PALOMO
CLINICAL PREDICTORS OF RESPONSE TO NALTREXONE IN ALCOHOLIC PATIENTS: WHO BENEFITS MOST FROM TREATMENT WITH NALTREXONE?
Alcohol Alcohol., May 1, 2005; 40(3): 227 - 233.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. C. Garbutt, H. R. Kranzler, S. S. O'Malley, D. R. Gastfriend, H. M. Pettinati, B. L. Silverman, J. W. Loewy, E. W. Ehrich, and for the Vivitrex Study Group
Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence: A Randomized Controlled Trial
JAMA, April 6, 2005; 293(13): 1617 - 1625.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A. R. Lingford-Hughes, S. Welch, and D. J. Nutt
Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology
J Psychopharmacol, September 1, 2004; 18(3): 293 - 335.
[PDF]

Home page
 J PsychopharmacolHome page
J. Chick, P. Lehert, and F. Landron
Does Acamprosate Improve Reduction of Drinking As Well As Aiding Abstinence?
J Psychopharmacol, December 1, 2003; 17(4): 397 - 402.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
S. S. O'Malley, B. J. Rounsaville, C. Farren, K. Namkoong, R. Wu, J. Robinson, and P. G. O'Connor
Initial and Maintenance Naltrexone Treatment for Alcohol Dependence Using Primary Care vs Specialty Care: A Nested Sequence of 3 Randomized Trials
Arch Intern Med, July 28, 2003; 163(14): 1695 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
F. Trumpler, S. Oez, P. Stahli, H. D. Brenner, and P. Juni
ACUPUNCTURE FOR ALCOHOL WITHDRAWAL: A RANDOMIZED CONTROLLED TRIAL
Alcohol Alcohol., July 1, 2003; 38(4): 369 - 375.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
A. H. Mack and R. J. Frances
Substance-Related Disorders
Focus, April 1, 2003; 1(2): 125 - 146.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
F. Kiefer, H. Jahn, T. Tarnaske, H. Helwig, P. Briken, R. Holzbach, P. Kampf, R. Stracke, M. Baehr, D. Naber, et al.
Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism: A Double-blind, Placebo-Controlled Study
Arch Gen Psychiatry, January 1, 2003; 60(1): 92 - 99.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
F. Weiss and L. J. Porrino
Behavioral Neurobiology of Alcohol Addiction: Recent Advances and Challenges
J. Neurosci., May 1, 2002; 22(9): 3332 - 3337.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Rubio, G. Ponce, J. Manzanares, J. D. Sinclair, H. Alho, M. Shinderman, J. H. Krystal, J. A. Cramer, and R. Rosenheck
Naltrexone for Alcohol Dependence
N. Engl. J. Med., April 25, 2002; 346(17): 1329 - 1331.
[Full Text] [PDF]

Home page
 NEJMHome page
J. H. Krystal, J. A. Cramer, W. F. Krol, G. F. Kirk, R. A. Rosenheck, and the Veterans Affairs Naltrexone Cooperative Study
Naltrexone in the Treatment of Alcohol Dependence
N. Engl. J. Med., December 13, 2001; 345(24): 1734 - 1739.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. K. Fuller and E. Gordis
Naltrexone Treatment for Alcohol Dependence
N. Engl. J. Med., December 13, 2001; 345(24): 1770 - 1771.
[Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
G. Rubio, M. A. Jimenez-Arriero, G. Ponce, and T. Palomo
NALTREXONE VERSUS ACAMPROSATE: ONE YEAR FOLLOW-UP OF ALCOHOL DEPENDENCE TREATMENT
Alcohol Alcohol., September 1, 2001; 36(5): 419 - 425.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
J. D. Sinclair
Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism
Alcohol Alcohol., January 1, 2001; 36(1): 2 - 10.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
H. R. Kranzler
PHARMACOTHERAPY OF ALCOHOLISM: GAPS IN KNOWLEDGE AND OPPORTUNITIES FOR RESEARCH
Alcohol Alcohol., November 1, 2000; 35(6): 537 - 547.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
J. Chick, R. Anton, K. Checinski, R. Croop, D. C. Drummond, R. Farmer, D. Labriola, J. Marshall, J. Moncrieff, M. Y. Morgan, et al.
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NALTREXONE IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ABUSE
Alcohol Alcohol., November 1, 2000; 35(6): 587 - 593.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Ment. HealthHome page
J. Chick
Naltrexone plus cognitive behavioural therapy led to fewer drinking relapses in outpatients with alcoholism
Evid. Based Ment. Health, August 1, 2000; 3(3): 75 - 75.
[Full Text]

Home page
 JWatch GeneralHome page
Another Look at Successful Pharmacotherapy for Alcoholism
Journal Watch (General), November 30, 1999; 1999(1130): 2 - 2.
[Full Text]


Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org